indications for glp 1 agonist The science on GLP-1 receptor agonists has outpaced the public narrative. While headlines chase the latest prescription numbers, evidence-based practice demands we hold the line: obesity is a chronic, relapsing condition; not Benefits and Risks of GLP-1
Description
At 10 years, the survival probability was 96.9% for GLP-1RA use and 76.4% for insulin/metformin use
It represents a potent new treatment option for individuals affected by obesity or overweight and weight-related medical issues
210,211 The weight loss effects from GLP-1 RA treatment may reverse these changes and alter the pharmacokinetics of co-administered lipophilic drugs by decreasing the Vd (Figure 3)
We use cookies to make your experience better
Nat Rev Dis Primers (2018) 4:18014
What can be used as a substitute for Ozempic
